Chengdu Origen Biotechnology Co., Ltd.
4 clinical trials · Sponsor
◉ Watch Chengdu Origen Biotechnology Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration (NCT06825858) | Chengdu Origen Biotechnology Co., Ltd. | 2025-04-07 |
| Safety and Tolerability of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD) (NCT06458595) | Chengdu Origen Biotechnology Co., Ltd. | 2024-06-28 |
| Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration (NCT05657301) | Chengdu Origen Biotechnology Co., Ltd. | 2023-10-16 |
| Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD) (NCT05672121) | Chengdu Origen Biotechnology Co., Ltd. | 2023-02-06 |
Track Chengdu Origen Biotechnology Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.